Interleukin-12 antitumor activities are mediated by the activation of T and NK lymphocytes to produce IFN gamma. Systemically, recombinant interleukin-12 has a narrow therapeutic window that favors local delivery, i.e., by gene therapy approaches. Interleukin-12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer.
from Cancer via ola Kala on Inoreader http://ift.tt/2pi0pkc
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου